Key result
Transcatheter tricuspid repair and replacement offer viable, less invasive options for severe tricuspid regurgitation.
Why the study?
Isolated tricuspid valve surgery is infrequent and has the highest mortality among valve procedures, creating a need for less invasive therapeutic options.
Tricuspid regurgitation is a common finding in patients with left-sided valvular or myocardial disease, often being a marker for late-stage chronic heart failure with a grim prognosis. However, isolated tricuspid valve surgery remains infrequent and is associated with the highest mortality among all valve procedures. Hence, a largely unmet clinical need exists for less invasive therapeutic options in these patients. In recent times, multiple percutaneous therapies have been developed for treating severe tricuspid regurgitation, including tricuspid valve repair and, more recently replacement, opening an entirely new venue for managing tricuspid regurgitation. The aim of this review is to provide an updated overview and a clinical perspective on novel transcatheter tricuspid valve therapies, highlighting potential challenges and future directions.
No takes yet. Share an insight, caveat, or question.
Asmarats et al. (2018) conducted a review in Tricuspid regurgitation. Transcatheter tricuspid valve therapies was evaluated. Transcatheter tricuspid valve therapies, including repair and replacement, have emerged as novel, less invasive therapeutic options for managing severe tricuspid regurgitation.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: